- Stock: Pre-Order
- Brand: Novo Nordisk
- Product ID: Protamine Crystallised Insulin Aspart
100% Secure Payment
bKash | Nagad | Cards via SSLCommerz | COD
Monthly Medicines Available | Free Delivery on Eligible Orders
This Item is for pre order
NovoRapid FlexPen – Insulin Aspart 100 IU/ml by Novo Nordisk
| Generic Name | Insulin Aspart |
| Brand Name | NovoRapid |
| Manufacturer | Novo Nordisk A/S (Denmark) |
| Dosage Form | Solution for Injection — Pre-filled FlexPen (3 ml) |
| Strength | 100 IU/ml (U-100) |
| Pack Size | 5 FlexPens × 3 ml = 1,500 IU total |
| Drug Class | Rapid-acting Insulin Analogue (Mealtime Insulin) |
| Prescription Required | Yes — Rx Only |
| Onset / Peak / Duration | Onset: 10–20 min | Peak: 1–3 hrs | Duration: 3–5 hrs |
What is NovoRapid FlexPen?
NovoRapid FlexPen is one of the world's most prescribed rapid-acting mealtime insulin analogues. Each pen contains insulin aspart 100 IU/ml — a modified human insulin acting faster and wearing off sooner than regular insulin. Manufactured by Novo Nordisk A/S (Denmark), the pre-filled FlexPen injects at or just before meals with action beginning within 10–20 minutes lasting 3–5 hours. Used as the bolus (mealtime) component in basal-bolus regimens in Type 1 and Type 2 diabetes, typically paired with a long-acting basal insulin (Tresiba, Levemir, or Lantus). Dials doses in 1-unit steps up to 60 IU per injection.
Generic Name & Composition
Each ml contains 100 IU of insulin aspart (rDNA origin). Insulin aspart has a single B28 substitution (proline → aspartate) that reduces self-association, allowing rapid monomeric absorption after subcutaneous injection. Onset 10–20 minutes, peak 1–3 hours, duration 3–5 hours — faster than regular human insulin (onset 30–60 min, duration 5–8 hrs).
Indications
- Type 1 diabetes — bolus (mealtime) component in basal-bolus regimen
- Type 2 diabetes — mealtime insulin when oral/non-insulin therapy is insufficient
- CSII (insulin pump) therapy — approved for continuous subcutaneous infusion
- Correction dosing for elevated post-meal blood glucose
How It Works — Mechanism of Action
The B28 substitution prevents hexamer formation, enabling rapid absorption as monomers. Peak plasma levels at 40–50 minutes — twice as fast as regular insulin. Activates insulin receptors: GLUT-4 glucose uptake in muscle and adipose, hepatic glucose suppression, glycogen and lipid synthesis — controlling post-meal blood glucose rise.
Dosage & Administration
Timing: 0–15 minutes before meals (or immediately after). Dose: Individualised — 4–15 IU per meal based on carbohydrate and correction factor. FlexPen: Remove cap, attach needle, prime 2 IU before first use, dial dose, inject subcutaneously, hold 6 seconds. Sites: Abdomen (fastest), thigh, upper arm. Rotate systematically.
Side Effects
Very common: Hypoglycaemia — most important risk of mealtime insulin.
Common: Injection site reactions, lipohypertrophy.
Uncommon: Lipoatrophy, peripheral oedema, transient visual changes at therapy initiation.
Rare: Anaphylaxis, severe allergic reactions.
Drug Interactions
Increase hypoglycaemia: Sulphonylureas, GLP-1 agonists, SGLT-2 inhibitors, ACE inhibitors, MAO inhibitors, salicylates, alcohol.
Reduce effect: Corticosteroids, glucagon, thyroid hormones, thiazides, sympathomimetics, atypical antipsychotics.
Caution: Beta-blockers mask hypoglycaemia symptoms.
Contraindications
- Hypersensitivity to insulin aspart or any excipient
- Active hypoglycaemia
Pregnancy & Lactation
Pregnancy: Insulin aspart approved for pregnancy; specialist supervision required as dose requirements change. Lactation: Safe; not expected at clinically significant concentrations in breast milk.
Precautions & Warnings
- Eat within 15 minutes — never inject if meal uncertain.
- Faster than regular insulin: Monitor closely when switching from regular insulin.
- Clear solution: Do not use if cloudy or discoloured.
Overdose
Hypoglycaemia lasting 3–5 hrs. Mild: oral glucose. Severe: IV dextrose or IM glucagon. Monitor until stable.
Storage Instructions
- Unopened: 2–8°C. Do not freeze.
- In-use pen: Below 30°C. Do not refrigerate.
- Discard 28 days after first use.
Frequently Asked Questions (FAQs)
Q1: How is NovoRapid different from regular human insulin (Actrapid)?
NovoRapid acts in 10–20 min vs 30–60 min for Actrapid, allowing injection right before meals. Duration is 3–5 hrs vs 5–8 hrs — less late hypoglycaemia risk. NovoRapid provides better post-meal control and more flexible meal timing.
Q2: Can NovoRapid be used in an insulin pump?
Yes — insulin aspart is approved for CSII pump therapy in Type 1 and Type 2 diabetes. One of the most commonly used pump insulins worldwide.
Q3: Do I need a separate long-acting insulin with NovoRapid?
Yes for most patients. NovoRapid covers only 3–5 hours. A separate basal insulin (Tresiba, Levemir, or Lantus) is needed for 24-hour glucose control in Type 1 and many Type 2 patients.
Q4: Who manufactures NovoRapid?
Novo Nordisk A/S (Denmark). NovoRapid (insulin aspart) has been in clinical use since 1999.
⚕ Medical Disclaimer: For educational purposes only. NovoRapid is Rx-only. Consult your diabetologist before changing insulin therapy. DiabetesStore.com.bd is a licensed online pharmacy.
